LTRN Lantern Pharma Inc.
USHealthcareAs of 2026-07-10 16:00
Why LTRN matters now
Lantern Pharma Inc. (LTRN) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.60 with +7.46% on the session and $45.9M in market capitalization; recent performance reads 1-month +22.65% and YTD +25.08%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.3M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -31.2%.
The latest indexable market news headline is "Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes KEYSER D JEFFREY filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.38
P/S
0.00
EV/EBITDA
-2.74
DCF Value
$-7.17
FCF Yield
-31.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1.0%
ROA
-220.3%
ROIC
-473.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.3M | $-0.30 |
| Q4 2025 | $0.00 | $-4.1M | $-0.36 |
| FY 2025 | $0.00 | $-17.1M | $-1.57 |
| Q3 2025 | $0.00 | $-4.2M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.32
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.